» Articles » PMID: 30305370

Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children

Abstract

Progression to clinical type 1 diabetes varies among children who develop β-cell autoantibodies. Differences in autoantibody patterns could relate to disease progression and etiology. Here we modeled complex longitudinal autoantibody profiles by using a novel wavelet-based algorithm. We identified clusters of similar profiles associated with various types of progression among 600 children from The Environmental Determinants of Diabetes in the Young (TEDDY) birth cohort study; these children developed persistent insulin autoantibodies (IAA), GAD autoantibodies (GADA), insulinoma-associated antigen 2 autoantibodies (IA-2A), or a combination of these, and they were followed up prospectively at 3- to 6-month intervals (median follow-up 6.5 years). Children who developed multiple autoantibody types ( = 370) were clustered, and progression from seroconversion to clinical diabetes within 5 years ranged between clusters from 6% (95% CI 0, 17.4) to 84% (59.2, 93.6). Children who seroconverted early in life (median age <2 years) and developed IAA and IA-2A that were stable-positive on follow-up had the highest risk of diabetes, and this risk was unaffected by GADA status. Clusters of children who lacked stable-positive GADA responses contained more boys and lower frequencies of the HLA-DR3 allele. Our novel algorithm allows refined grouping of β-cell autoantibody-positive children who distinctly progressed to clinical type 1 diabetes, and it provides new opportunities in searching for etiological factors and elucidating complex disease mechanisms.

Citing Articles

Looking back at the TEDDY study: lessons and future directions.

Lernmark A, Agardh D, Akolkar B, Gesualdo P, Hagopian W, Haller M Nat Rev Endocrinol. 2024; 21(3):154-165.

PMID: 39496810 PMC: 11825287. DOI: 10.1038/s41574-024-01045-0.


Blood immune cell profiling in adults with longstanding type 1 diabetes is associated with macrovascular complications.

He X, Wang X, van Heck J, van Cranenbroek B, van Rijssen E, Stienstra R Front Immunol. 2024; 15:1401542.

PMID: 39011037 PMC: 11246869. DOI: 10.3389/fimmu.2024.1401542.


Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles.

Ghalwash M, Anand V, Ng K, Dunne J, Lou O, Lundgren M Diabetes Care. 2024; 47(8):1424-1431.

PMID: 38861550 PMC: 11272969. DOI: 10.2337/dc24-0198.


The immunology of type 1 diabetes.

Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L Nat Rev Immunol. 2024; 24(6):435-451.

PMID: 38308004 PMC: 7616056. DOI: 10.1038/s41577-023-00985-4.


Heterogeneity and endotypes in type 1 diabetes mellitus.

Redondo M, Morgan N Nat Rev Endocrinol. 2023; 19(9):542-554.

PMID: 37337007 DOI: 10.1038/s41574-023-00853-0.


References
1.
Mayr A, Schlosser M, Grober N, Kenk H, Ziegler A, Bonifacio E . GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes. 2007; 56(6):1527-33. DOI: 10.2337/db06-1715. View

2.
Ilonen J, Hammais A, Laine A, Lempainen J, Vaarala O, Veijola R . Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes. 2013; 62(10):3636-40. PMC: 3781470. DOI: 10.2337/db13-0300. View

3.
. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007; 8(5):286-98. DOI: 10.1111/j.1399-5448.2007.00269.x. View

4.
Bingley P . Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2009; 95(1):25-33. DOI: 10.1210/jc.2009-1365. View

5.
De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I . Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease:.... Diabetologia. 2010; 53(3):517-24. DOI: 10.1007/s00125-009-1618-y. View